Table 3. Flow cytometry data.* .
| Flow parameter | Enrollment(n = 14) | Mean at 7th Dose | Change at 7th Dose(n = 13) | P value** |
|---|---|---|---|---|
| Mean (SD), Median (25%, 75%) | N, Mean (SD), Median (25%, 75%) | Mean (SE) | ||
| % CD3 + from CD45 + | 44.4 (17.4), 47.2 (34.6, 58.9) | |||
| Enrollment vs. RF D7 | 11, 53.8 (16.4), 54.8 (46.9, 66.2) | 12.23 (5.89) | 0.0380 | |
| Enrollment vs. HEC/VF D7 | 12, 54.6 (18.9), 58.3 (49.8, 63.4) | 11.98 (3.46) | 0.0005 | |
| % CXCR4 + from CD4 + | 71.5 (16.1), 70.3 (57.9, 84.5) | |||
| Enrollment vs. HEC/VF D7 | 12, 61.1 (23.2), 61.4 (55.0, 79.5) | -10.68 (5.40) | 0.0480 | |
| Change at 7th Dose (RGVF v HEC/VF) | 16.4 (6.70) | 0.0142 | ||
| % CD69 + from CD4 + | 83.4 (6.0), 83.9 (80.4, 87.4) | |||
| Enrollment vs. HEC/VF D7 | 12, 80.5 (4.9), 82.3 (78.7, 83.5) | -2.27 (0.97) | 0.0188 | |
| % CXCR4 + and CCR5 + from CD4 + | 55.6 (11.9), 55.1 (43.8, 66.2) | |||
| Enrollment vs. HEC/VF D7 | 12, 45.4 (15.9), 48.7 (41.2, 53.9) | -10.16 (4.20) | 0.0157 | |
| Change at 7th Dose (RGVF v HEC/VF) | 15.70 (5.58) | 0.0049 | ||
| % CXCR4 + from CD8 + | 51.2 (17.1), 47.8 (40.2, 68.1) | |||
| Enrollment vs. HEC/VF D7 | 12, 39.3 (18.8), 38.3 (33.9, 54.2) | -13.38 (4.58) | 0.0035 | |
| % CD69 + from CD8 + | 85.7 (6.1), 84.7 (82.1, 90.5) | |||
| Enrollment vs. RGVF D7 | 13, 71.4 (26.6), 80.2 (78.1, 84.3) | -13.54 (6.17) | 0.0283 | |
| Change at 7th Dose (RF v RGVF) | 12.80 (6.02) | 0.0336 | ||
| % CXCR4 + and CCR5 + from CD8 + | 43.2 (13.1), 42.5 (35.6, 48.0) | |||
| Enrollment vs. HEC/VF D7 | 12, 31.5 (13.8), 34.0 (29.1, 37.7) | -12.51 (3.66) | 0.0006 |
*Table 3 only lists phenotypes where significant variation was noted between visits of between products. Complete flow cytometry data are provided in S1 Table
**P-value from significance test of relevant contrast from GEE model.